Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Division of Geriatrics and Gerontology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
BMC Palliat Care. 2021 Jan 12;20(1):13. doi: 10.1186/s12904-021-00710-9.
Artificial nutrition and hydration do not prolong survival or improve clinical symptoms of terminally ill cancer patients. Nonetheless, little is known about the effect of artificial hydration (AH) alone on patients' survival, symptoms or quality of dying. This study explored the relationship between AH and survival, symptoms and quality of dying among terminally ill cancer patients.
A pilot prospective, observational study was conducted in the palliative care units of three tertiary hospitals in Taiwan between October 2016 and December 2017. A total of 100 patients were included and classified into the hydration and non-hydration group using 400 mL of fluid per day as the cut-off point. The quality of dying was measured by the Good Death Scale (GDS). Multivariate analyses using Cox's proportional hazards model were used to assess the survival status of patients, the Wilcoxon rank-sum test for within-group analyses and the Mann-Whitney U test for between-groups analyses to evaluate changes in symptoms between day 0 and 7 in both groups. Logistic regression analysis was used to assess the predictors of a good death.
There were no differences in survival (p = 0.337) or symptom improvement between the hydration and non-hydration group, however, patients with AH had higher GDS scores.
AH did not prolong survival nor significantly improve dehydration symptoms of terminally ill cancer patients but it may influence the quality of dying. Communication with patients and their families on the effect of AH may help them better prepared for the end-of-life experience.
人工营养和水合作用并不能延长终末期癌症患者的生存时间或改善其临床症状。尽管如此,人们对单独进行人工水合作用(AH)对患者生存、症状或临终质量的影响知之甚少。本研究旨在探讨终末期癌症患者 AH 与生存、症状和临终质量之间的关系。
本研究为一项于 2016 年 10 月至 2017 年 12 月在台湾三家三级医院姑息治疗病房进行的前瞻性观察性试点研究。共纳入 100 例患者,以每天 400ml 液体为界值分为水化组和非水化组。采用 Good Death Scale(GDS)评估临终质量。采用 Cox 比例风险模型的多变量分析评估患者的生存状况,采用 Wilcoxon 秩和检验进行组内分析,采用 Mann-Whitney U 检验进行组间分析,评估两组患者在第 0 天和第 7 天之间症状的变化。采用逻辑回归分析评估良好死亡的预测因素。
水化组与非水化组的生存情况(p=0.337)或症状改善情况无差异,但 AH 组的 GDS 评分更高。
AH 并不能延长终末期癌症患者的生存时间,也不能显著改善其脱水症状,但可能会影响临终质量。与患者及其家属就 AH 的效果进行沟通,可能有助于他们更好地为临终体验做好准备。